Editor’s note: The article has been corrected to remove a reference to Novozymes North America being a subsidiary of Novo Nordisk. The 17 pharmaceutical companies anchoring TrumpRx, the White House’s new prescription drug-pricing program, poured more than $130 million into federal lobbying in 2025 – a nearly 23% surge that outpaced the broader industry as the plan was being shaped behind the scene...